Cite
HARVARD Citation
Boorjian, S. et al. (2021). Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet oncology. 22 (1), pp. 107-117. [Online].